A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone and treating unresectable giant cell tumor of ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

Denosumab, a fully human antibody against receptor activator of NF-κB ligand, and alendronate, a bisphosphonate, have different mechanisms of action in preventing structural decay of bone in patients ...

S&P Global Ratings on Wednesday upgraded Biocon Biologics ratings with a stable outlook.

Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be ...

Learn about osteoporosis, its risks, symptoms, and prevention strategies to maintain bone health and prevent fractures.

Amgen Inc. reports fourth-quarter earnings today after the bell, putting the spotlight on how the $185.6 billion biotechnology giant plans to navigate a year marked by significant biosimilar ...